Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing...
Idorsia enters into exclusive negotiations for global rights to aprocitentan Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for...
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX:...
Idorsia announces financial results for the first nine months of 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced...
New data on aprocitentan to be presented at the ASN Kidney Week 2024 Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s...
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX:...
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil...
Amended terms of Idorsia’s 2024 convertible bonds become effective Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced...
Idorsia announces financial results for the first half 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its...
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관